In addition, there are no treatments available to avoid this condition4 and current therapies only slow the advancement of the disease.4 Thus, there is an intense need for the development of easy analytical tools for the rapid detection of AD biomarkers for early-stage point-of-care diagnosis.5–7 Aβ(1–42) peptide is the key element of the senile plaques present in AD.8 Other pathological characteristics of AD consist of intraneuronal inclusions of hyperphosphorylated tau protein in neurofibrillary tangles, together with downstream processes such as inflammation and oxidative stress. Here, MAPT is linked to Alzheimer disease.